Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21819163 | 0.67 | KDM4E (0.38) | L3MBTL1SMN1; SMN2KDM4C | |
| SCHEMBL31133522 | 0.67 | KDM4E (0.38) | L3MBTL1SMN1; SMN2KDM4C | |
| SCHEMBL1816921 | 0.67 | NUDT1 (0.35) | — | |
| SCHEMBL23012585 | 0.65 | L3MBTL1 (0.44) | L3MBTL1XDHSLC22A12PDE10A | |
| SCHEMBL12238197 | 0.65 | L3MBTL1 (0.56) | L3MBTL1XDHSLC22A12DHODHSMN1; SMN2 | |
| SCHEMBL6568411 | 0.64 | SMN1; SMN2 (0.38) | XDHSLC22A12SMN1; SMN2KDM4C | |
| SCHEMBL21818593 | 0.64 | ACHE (0.40) | L3MBTL1SMN1; SMN2KDM4C | |
| Hydrochloric Acid SCHEMBL15995962 | 0.64 | L3MBTL1 (0.54) | L3MBTL1XDHSLC22A12DHODHSMN1; SMN2 | |
| SCHEMBL14554102 | 0.64 | HPGD (0.32) | SMN1; SMN2 | |
| SCHEMBL15896720 | 0.62 | XDH (0.42) | L3MBTL1XDHSLC22A12DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1696921-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058325-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | GIPR, SLC10A2, GRPR | L3MBTL1 4766/4885XDH 2135/4885SLC22A12 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.